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Acinetobacter infections have increased and gained
attention because of the organism’s prolonged environ-
mental survival and propensity to develop antimicrobial
drug resistance. The effect of multidrug-resistant (MDR)
Acinetobacter infection on clinical outcomes has not been
reported. Aretrospective, matched cohort investigation was
performed at 2 Baltimore hospitals to examine outcomes of
patients with MDR Acinetobacter infection compared with
patients with susceptible Acinetobacter infections and
patients without Acinetobacter infections. Multivariable
analysis controlling for severity of illness and underlying
disease identified an independent association between
patients with MDR Acinetobacter infection (n = 96) and
increased hospital and intensive care unit length of stay
compared with 91 patients with susceptible Acinetobacter
infection (odds ratio [OR] 2.5, 95% confidence interval [CI]
1.2–5.2 and OR 2.1, 95% CI 1.0–4.3] respectively) and 89
uninfected patients (OR 2.5, 95% CI 1.2–5.4 and OR 4.2,
95% CI 1.5–11.6] respectively). Increased hospitalization
associated with MDR Acinetobacter infection emphasizes
the need for infection control strategies to prevent cross-
transmission in healthcare settings.
A
cinetobacter species are aerobic gram-negative bacilli
that can cause healthcare-associated infections and can
survive for prolonged periods in the environment and on
the hands of healthcare workers (1–3). The proportion of
healthcare-associated infections caused by Acinetobacter
spp. has increased over the past decade in the United States
(4). Furthermore, Acinetobacter infections have become
increasingly difficult to treat because of the emergence of
strains resistant to all drugs or all but 1 commonly pre-
scribed antimicrobial drug (5–7). These multidrug-resist-
ant (MDR) strains are sometimes susceptible only to
polymyxins (colistin and polymyxin B), a class of antimi-
crobial drugs that has not been in widespread use for sev-
eral decades and is more toxic than most currently used
antimicrobial drugs. Outbreaks caused by MDR
Acinetobacter have been reported in hospitals all over the
world; more recently, they have become a serious problem
in military medical facilities (7–9).
Although drug resistance of Acinetobacter is a recog-
nized problem, the effect of MDR Acinetobacter infections
on patient outcomes remains controversial. Previous stud-
ies on clinical outcomes of patients infected with
Acinetobacter have yielded conflicting results and are lim-
ited by methodologic challenges that include small sample
sizes, failure to control for severity of illness before infec-
tion, and failure to exclude patients colonized with
Acinetobacter (10–14). Furthermore, most studies do not
differentiate outcomes of patients infected with MDR
Acinetobacter from those infected with drug-susceptible
Acinetobacter. This finding leads to questions about the
merits of targeting infection control measures to control
MDR  Acinetobacter. To determine the effect of MDR
Acinetobacter infection on mortality rates, length of hospi-
tal stay, and length of intensive care unit (ICU) stay, the
University of Maryland Medical Center, The Johns
Hopkins Hospital, the Maryland Department of Health and
Mental Hygiene, and the Centers for Disease Control and
Prevention collaborated to perform a retrospective,
matched, cohort study in Baltimore, Maryland. This is the
first study that directly examines the effect of multidrug
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Methods
Study Design
A retrospective, matched cohort investigation was
performed by using patient records from January 2003
through August 2004 from 2 tertiary care hospitals in
Baltimore to examine outcomes of hospitalized patients
with MDR Acinetobacter infection (exposure) compared
with 2 unexposed reference groups: patients with suscepti-
ble  Acinetobacter infection (susceptible references) and
patients without Acinetobacter infection (uninfected refer-
ences). We chose 2 reference groups to explore the effects
of multidrug resistance and MDR Acinetobacter infection
on patient outcomes (15). We defined MDR Acinetobacter
as organisms resistant to all or all but 1 antimicrobial drug
classes commonly prescribed to treat gram-negative infec-
tions. Susceptibility to polymyxins was not considered in
these criteria because susceptibility testing for these drugs
is not routinely performed. We defined susceptible
Acinetobacter as organisms susceptible to >3 antimicro-
bial classes. Those patients infected with Acinetobacter
that was susceptible to only 2 antimicrobial drug classes
were excluded.
Acomputer-generated list was used to identify all per-
sons from whom MDR Acinetobacter had been recovered
from January 2003 through August 2004. Charts were then
reviewed to determine, on the basis of criteria set forth by
the National Nosocomial Infection Surveillance System
(NNIS) (16), if the patient had 1 of the following infec-
tions caused by MDR Acinetobacter: bloodstream, pneu-
monia (respiratory tract), surgical site, urine, or sterile site
other than blood. Admitted patients with both healthcare-
acquired (i.e., infection was diagnosed >48 h after hospital
admission) and community-acquired Acinetobacter infec-
tions (i.e., infection was diagnosed within 48 h of hospital
admission) were included.
For the selection of matched susceptible references,
microbiology records were reviewed to identify patients
from whom susceptible Acinetobacter had been recovered
from January 2003 through August 2004 at each institu-
tion. NNIS definitions were then applied to identify
Acinetobacter-infected patients who were included in the
study (16). To ensure that susceptible references and their
matched MDR Acinetobacter patients had a similar expo-
sure time, the susceptible references had to have a prein-
fection length of hospital stay within 5% of the matched
MDR Acinetobacter patient’s preinfection length of stay.
Patients infected with MDR Acinetobacter were matched
to susceptible references from the same institution.
The second reference group, uninfected patients,
included patients without Acinetobacter infection who had
a length of hospital stay (time between admission and dis-
charge) at least as long as the preinfection length of stay of
the respective matched patient infected with MDR
Acinetobacter. The matched uninfected patient also had to
be present in the ward where the patient infected with
MDR Acinetobacter was located within 30 days of becom-
ing infected with MDR Acinetobacter.
Data abstracted from medical records included demo-
graphic information; presence of prior and concurrent
medical conditions; dates of admission and discharge to
the ICU and hospital; date and time of Acinetobacter cul-
ture;  Acinetobacter antimicrobial susceptibility pattern;
length of stay before infection (exposure time); presence or
absence of concordant antimicrobial therapy on the day of
the Acinetobacter culture (based on the susceptibility pat-
tern of the organism); patient status on day of discharge;
and date and cause of death if applicable. Data were col-
lected on the following outcomes: in-hospital mortality
rates and total number of days in hospital and ICU after the
index day (i.e., length of stay after the exposure). We
defined the index day as either the day of hospitalization
on which Acinetobacter infection was diagnosed for
patients infected with MDR Acinetobacter and for suscep-
tible reference patients or the same day of hospitalization
for uninfected patients. For example, if an MDR
Acinetobacter infection was diagnosed on hospital day 15,
that would be the index day for the MDR Acinetobacter
patient and for the matched, uninfected patient.
To control for severity of illness before Acinetobacter
infection, data were collected to calculate a modified
Acute Physiology and Chronic Health Evaluation III
(APACHE) score (17,18) ≈48 h before the index day. Our
modified APACHE score did not include blood pH, pul-
monary arterial oxygen saturation, pulmonary arterial gra-
dient, urine output, or scoring for neurologic
abnormalities. These parameters were excluded because
they were not uniformly available for all patients in the
study, particularly for those not in the ICU. To control for
underlying disease, a Charlson comorbidity index (19) was
calculated by using data from the medical history recorded
on the chart.
Statistical Analysis
All data were collected on standard forms, entered into
an Access database (Microsoft, Redmond, WA, USA) and
analyzed with SAS software (SAS Institute, Cary, NC,
USA). Demographic data were analyzed with Mantel-
Haenszel relative risks and 95% confidence intervals (CIs)
to compare categorical variables and the Wilcoxon 2-sam-
ple test with t approximation to compare continuous vari-
ables. Matched univariate analysis was performed by using
conditional logistic regression. Multivariable analysis con-
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underlying diseases with the Charlson index was performed
by using conditional logistic regression to evaluate in-
hospital mortality rate and hospital and ICU length of stay.
To create a dichotomous variable for ICU and hospi-
tal lengths of stay, we compared the number in each com-
parison group that had a length of stay greater than the
combined mean of the 2 groups being compared. For
example, the combined group of MDR Acinetobacter–
infected and susceptible Acinetobacter references had a
mean hospital length of stay of 23 days after the index day
(day of infection). The number of MDR Acinetobacter
patients who had a hospital length of stay >23 days was
then compared with the number of susceptible references
who had a hospital length of stay >23 days, while control-
ling for severity of illness and associated underlying dis-
eases in the multivariable model. We chose to compare
against the mean rather than the median length of stay to
account for outliers. Unmatched MDR Acinetobacter–
infected and reference patients were excluded from the
groups before the mean was calculated. Alinear regression
model and an ordinal logistic regression model were also
attempted; however, these models could not be used
because the outcome data were not normally distributed
and could not be transformed appropriately for linear
regression and because the assumptions for the ordinal
logistic regression model could not be satisfied.
To examine the effect of discordant empiric antimicro-
bial drug therapy on clinical outcomes, multivariable
analysis was performed on the MDR Acinetobacter
patients alone; the exposure evaluated was concordant ver-
sus discordant empiric antimicrobial drug therapy.
Outcomes included mortality rate, length of hospital stay,
and ICU stay. We defined discordant empiric antimicrobial
drug therapy as the administration of antimicrobial drug(s)
to which the Acinetobacter strain was not susceptible.
Concordant empiric antimicrobial drug therapy is defined
as the administration of antimicrobial drug(s) to which the
Acinetobacter strain was susceptible. APACHE and
Charlson index scores were included in the model to con-
trol for their effect on outcomes.
Effect modification between MDR Acinetobacter ref-
erence groups and APACHE and Charlson index variables
was evaluated by testing appropriate interaction terms for
statistical significance. All statistical tests were 2-tailed; a
p value <0.05 was considered statistically significant.
Results
From January 2003 through August 2004, a total of
166 patients had cultures that grew MDR Acinetobacter,
and 96 (58%) met the NNIS criteria for an MDR
Acinetobacter infection (16). Of the MDR isolates, 88
(92%) were not susceptible to carbapenems.
MDR Acinetobacter–infected Patients Compared 
with Susceptible References
We identified 91 reference patients infected with sus-
ceptible Acinetobacter who had similar lengths of hospital
stay before the index day as MDR Acinetobacter–infected
patients. Five MDR Acinetobacter–infected patients were
excluded from the analysis because reference patients could
not be identified due to a lack of susceptible references who
were hospitalized for long periods. MDR Acinetobacter
patients and susceptible references were similar in age and
sex; however, MDR Acinetobacter patients had higher
baseline mean APACHE and Charlson index scores than
susceptible references (Table 1). The distribution of culture
sites among MDR Acinetobacter and susceptible reference
patients was similar; ≈50% of each group had respiratory
infections, 31% in each group had bloodstream infections,
and <10% of both groups had surgical wound, urinary tract,
or other sterile site infections (p not significant for all com-
parisons). A total of 78 (81%) MDR Acinetobacter infec-
tions and 73 (80%) susceptible Acinetobacter infections
were identified >48 h after hospital admission and thus met
criteria for nosocomial infection.
Matched univariate analysis of patient outcomes
showed that MDR Acinetobacter–infected patients had
higher mean lengths of hospital stay and ICU stay after the
index day than susceptible and uninfected references
(Table 2). In-hospital mortality rates for patients with
MDR Acinetobacter infections (26%) were higher than for
susceptible references (18%) and uninfected references
(11%). However, only the difference between MDR
Acinetobacter–infected patients and uninfected patients
was statistically significant (Table 2). When controlling for
severity of illness with the APACHE score and for under-
lying disease with the Charlson index in a conditional
logistic regression model, association with a longer hospi-
tal and ICU length of stay was approximately twice as like-
ly for patients with MDR Acinetobacter infection as for
susceptible references (Table 3). Multivariable analysis
controlling for severity of illness with the APACHE score
and underlying diseases with the Charlson index showed a
trend toward more deaths associated with infection with
MDR Acinetobacter than with infection with susceptible
Acinetobacter, but the difference was not statistically sig-
nificant (relative risk 2.6, 95% CI 0.3–26.1) (Table 3).
Discordant antimicrobial drug therapy was more com-
mon for MDR Acinetobacter–infected patients than for
susceptible references (91% vs. 65%, p<0.001). When we
controlled for severity of illness and underlying diseases,
we found that initial discordant antimicrobial drug therapy
was not associated with increased mortality rates or hospi-
tal length of stay among patients infected with MDR
Acinetobacter (Table 4). However, patients infected with
MDR Acinetobacter who were treated with initial discor-
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associated with an increased ICU length of stay.
MDR Acinetobacter–infected Patients Compared 
with Uninfected References
Uninfected reference patients were identified for 89 of
96 patients with MDR Acinetobacter infections. Reference
patients were not identified for 7 MDR Acinetobacter
patients because there were not enough uninfected patients
with extensive hospital lengths of stay. MDR
Acinetobacter–infected patients and uninfected references
were similar in age and sex. However, patients with MDR
Acinetobacter infection had higher baseline mean
APACHE and Charlson index scores than references
(Table 1). Matched univariate analysis of patient outcomes
showed that patients with MDR Acinetobacter had higher
in-hospital mortality rates (26% vs. 11%, p<0.01) and
mean hospital and ICU lengths of stay after the index day
than uninfected references (Table 2). When we controlled
for severity of illness and underlying conditions, we found
that MDR Acinetobacter–infected patients were more like-
ly to have both longer hospital and ICU lengths of stay
than uninfected references (Table 3).
Discussion
Acinetobacter is emerging as an important pathogen
in traditional and nontraditional healthcare settings. Its
ability to infect healthy hosts and its propensity to develop
antimicrobial drug resistance have caused concern among
the infectious diseases community. Our study assessed the
clinical outcomes of patients infected with MDR
Acinetobacter compared with outcomes of patients infect-
ed with susceptible Acinetobacter strains and patients
without Acinetobacter infections among a large cohort. We
demonstrated that patients infected with MDR strains of
Acinetobacter have longer lengths of stay in both the hos-
pital and ICU than patients infected with drug-susceptible
Acinetobacter and patients without Acinetobacter infec-
tion when we controlled for severity of illness. We found a
trend toward increased mortality rates among patients with
MDR  Acinetobacter infection. However, the difference
was not statistically significant when we controlled for
severity of illness.
According to NNIS, Acinetobacter species caused 7%
of ICU healthcare-associated pneumonias in 2003 com-
pared with 4% in 1986 (p<0.001) (4). The proportion of
ICU healthcare-associated urinary tract infections and sur-
gical site infections caused by Acinetobacter also
increased significantly from 1986 to 2003 (p<0.001) (4).
Furthermore, the proportions of Acinetobacter isolates
reported to NNIS that were resistant to ceftazidime,
amikacin, and imipenem all increased significantly during
that period (p<0.001). Healthcare-associated outbreaks of
MDR Acinetobacter infection have been reported in Asia,
Europe, North America, and among US service members
injured in the Middle East (7–9). These findings have
brought control of MDR Acinetobacter infections to the
forefront of discussion.
Investigating the effect of multidrug resistance on
clinical outcomes presents multiple methodologic chal-
lenges that have been explicitly addressed in our study
design. Confounding risk factors associated with mortali-
ty rates and antimicrobial drug resistance, such as age,
severity of illness, and underlying disease (18–21) must
be controlled for in the study design or analysis. Our
results differ from those of researchers who examined out-
comes of Acinetobacter infections without controlling for
these confounders (14,22,23), which makes their findings
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ity of illness and underlying disease with 2 measurements:
the APACHE score, which included age, physiologic
parameters, and selected underlying diseases; and a sepa-
rate Charlson index, which included a broader range of
underlying diseases. Both measurements have been vali-
dated, although the APACHE score has only been studied
in its original form (19,21,24). Because patients infected
with  Acinetobacter have worse clinical outcomes than
those who are colonized with the organism (11), we sepa-
rated  Acinetobacter infection from colonization on the
basis of standardized, validated Centers for Disease
Control and Prevention (Atlanta, GA, USA) NNIS defini-
tions for nosocomial infection (16,25) and applied them
uniformly to MDR Acinetobacter and susceptible refer-
ences. We compared outcomes of MDR Acinetobacter
infections with those of 2 reference groups and showed an
association of MDR Acinetobacter infection with both
increased hospital and ICU lengths of stay, regardless of
the reference group selected. As one would predict on the
basis of results of a study by Kaye et al., the effect of mul-
tidrug resistance was greater compared with uninfected
than susceptible references (15).
Because of the lack of a standard definition for mul-
tidrug resistance in the literature, we defined multidrug
resistance as resistance to all or all but 1 antimicrobial drug
class commonly prescribed for treatment of patients with
gram-negative infections, with the exclusion of polymyx-
ins (26). This definition has 2 advantages. First, it is a strict
standard and is readily accepted by clinicians as represen-
tative of multidrug resistance. Second, it allows for a clear
distinction between susceptible and MDR Acinetobacter
strains because we excluded isolates that showed interme-
diate resistance (strains resistant to all but 2 commonly
prescribed antimicrobial drug classes).
The association of MDR Acinetobacter infections
with worse clinical outcomes could be related to discor-
dant empiric antimicrobial drug therapy. Previous studies
that examined the effects of delayed concordant antimi-
crobial therapy on patient outcomes have shown conflict-
ing results (27–29). We examined this issue and found that
patients with MDR Acinetobacter infections who received
discordant empiric antimicrobial drug therapy were not
more likely to die or have a longer hospital length of stay
than patients who received concordant empiric drug ther-
apy; however, they were more likely to have a longer ICU
length of stay. On the basis of these results, to what extent
discordant empiric antimicrobial drug therapy affects
clinical outcomes of MDR Acinetobacter infection is
not clear.
Determining optimal infection control approaches to
MDR Acinetobacter has been complicated by the lack of
agreement on the clinical significance of Acinetobacter
infections. The Hospital Infection Control Practices
Advisory Committee guideline for isolation precautions in
hospitals recommends targeting increased infection con-
trol efforts toward “resistant bacteria judged by the infec-
tion control program to be of special clinical and
epidemiologic significance” (30). We found that MDR
Acinetobacter infections are independently associated with
increased hospital and ICU lengths of stay. This finding,
combined with increased risk for in-hospital transmission
of the organism (31), supports recommendations to imple-
ment aggressive control measures to limit the transmission
of MDR Acinetobacter in healthcare settings.
Several limitations of this study merit discussion.
Because of the lack of available data to calculate a stan-
dard APACHE III score for non-ICU patients, we modified
the APACHE III score by excluding variables that were
unavailable for non-ICU patients. However, our findings
Multidrug-resistant Acinetobacter Infection
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severity of underlying illness. Mean APACHE scores were
higher in MDR Acinetobacter–infected patients than in
both reference groups and progressed stepwise from no
infection to MDR infection. These findings are expected
because drug-resistant infections reportedly occur in sick-
er patients (24,32,33). Univariate analysis showed that a
modified APACHE score was also associated with mortal-
ity rates (p<0.001), which further supports its validity as a
measure of illness severity.
The lack of available reference patients with similar
exposure times to several of the case-patients (5 suscepti-
ble references and 7 uninfected references) was a second
limitation because we were obligated to exclude
unmatched MDR Acinetobacter–infected patients from
our analysis. These excluded patients typically had pro-
longed exposure times and tended to have long hospital
and ICU lengths of stay after infection. Exclusion of these
patients decreased the power of our study and likely biased
our results toward showing no difference in hospital or
ICU length of stay between the groups. Finally, the lack of
a difference in mortality rates, according to multivariable
analysis, could mean that MDR Acinetobacter are not
more virulent than nonresistant strains or that the sample
size in this study lacked the power to show a difference.
Our study indicates that infections with MDR
Acinetobacter are independently associated with the
adverse clinical outcomes of prolonged hospital and ICU
lengths of stay compared with the outcomes for uninfected
patients and those infected with drug-susceptible
Acinetobacter. This is the first study evaluating length of
stay and mortality rates associated with MDR
Acinetobacter infection while controlling for important
confounders such as severity of illness and underlying dis-
ease. These data emphasize the need for aggressive infec-
tion control strategies to prevent MDR Acinetobacter
infection and its adverse effects on hospitalized patients.
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